-
Product Name
Lifastuzumab vedotin reference antibody
- Documents
-
Description
Anti-NaPi2b / SLC34A2 Antibody (Lifastuzumab vedotin)
-
Tested applications
ELISA
-
Species reactivity
Human NaPi2b / SLC34A2
-
Isotype
IgG1
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-NaPi2b / SLC34A2 Antibody (Lifastuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-NaPi2b / SLC34A2 Antibody (Lifastuzumab vedotin) is more than 95%, determined by SEC-HPLC.
HIC-HPLC
The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Antibody (Lifastuzumab vedotin) is 3.7.
ELISA
Human NaPi2b CHO-S Cells were stained with Anti-NaPi2b / SLC34A2 Antibody (Lifastuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS
Bioactivity: FACS
Human NaPi2b HEK293 Cell Line were stained with Anti-NaPi2b / SLC34A2 Antibody (lifastuzumab vedotin)and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.9793 ug/mL.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"